|Articles|August 10, 2022
- Pharmaceutical Executive-08-01-2022
- Volume 42
- Issue 8
Pharmaceutical Executive, August 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 4 years ago
The Silver Lining Of Innovation in Genetic Medicinealmost 4 years ago
Navigating the Financial Meltdown for Biopharmaalmost 4 years ago
A Cross-Functional Formula: Operationalizing the Broader Role of Accessalmost 4 years ago
The Potential of Proteomicsalmost 4 years ago
Getting ‘Personal’ With Vaccine Developmentalmost 4 years ago
The Price of Innovation: ‘Paying for a Cure’ Remains Costly Propositionalmost 4 years ago
Milestones and Momentum: Assessing Advancements in Personalized Medicinealmost 4 years ago
A World of Opportunityalmost 4 years ago
Has Biotech Bottomed Out—and is Recent Recovery Sustainable?Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Industry’s Communication and Engagement with FDA
2
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
3
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
4
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
5